Androgen regulated nucleic acid molecules and encoded proteins
OwnerBiaoyang Lininventor
Life of this patent
Estimating the term…
Abstract
The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.
Claims241
A substantially pure ARP7 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 1.
A substantially pure ARP7 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1-445 of SEQ ID NO:
- 1.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP7 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 1;
- (b) determining a test expression level of ARP7 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP7 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP7 binding agent that selectively binds an ARP7 polypeptide;
- (b) determining a test expression level of ARP7 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP7 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP7 regulatory agent.
A substantially pure ARP15 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 3.
A substantially pure ARP15 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1-86 of SEQ ID NO:
- 3.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP15 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 3;
- (b) determining a test expression level of ARP15 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP15 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP15 binding agent that selectively binds an ARP15 polypeptide;
- (b) determining a test expression level of ARP15 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP15 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP15 regulatory agent.
A substantially pure ARP16 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP16 polypeptide having at least 90% amino acid identity with SEQ ID NO:
- 6.
A substantially pure ARP16 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1-1531 of SEQ ID NO:
- 5.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP16 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 5;
- (b) determining a test expression level of ARP16 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP16 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP16 polypeptide, comprising an amino acid sequence having at least 90% amino acid identity with SEQ ID NO:
- 6.
A substantially pure ARP16 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 6.
An ARP16 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of the ARP16 polypeptide SEQ ID NO:
- 6.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP16 binding agent that selectively binds an ARP16 polypeptide;
- (b) determining a test expression level of ARP16 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP16 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP16 regulatory agent.
A substantially pure ARP8 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP8 polypeptide having at least 65% amino acid identity with SEQ ID NO:
- 8.
A substantially pure ARP8 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1-349 of SEQ ID NO:
- 7.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP8 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 7;
- (b) determining a test expression level of ARP8 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP8 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP8 polypeptide, comprising an amino acid sequence having at least 65% amino acid identity with SEQ ID NO:
- 8.
A substantially pure ARP8 polypeptide fragment, comprising at least eight contiguous amino acids of residues 1-116 of SEQ ID NO:
- 8.
A substantially pure ARP8 polypeptide fragment, comprising at least eight contiguous amino acids of residues 249-576 of SEQ ID NO:
- 8.
An ARP8 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of residues 1-116 of SEQ ID NO:
- 8.
An ARP8 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of residues 249-576 of SEQ ID NO:
- 8.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP8 binding agent that selectively binds an ARP8 polypeptide;
- (b) determining a test expression level of ARP8 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP8 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP8 regulatory agent.
A substantially pure ARP9 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP9 polypeptide having at least 65% amino acid identity with SEQ ID NO:
- 10.
A substantially pure ARP9 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 697-745 of SEQ ID NO:
- 9.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP9 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 9;
- (b) determining a test expression level of ARP9 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP9 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP9 polypeptide, comprising an amino acid sequence having at least 65% amino acid identity with SEQ ID NO:
- 10.
A substantially pure ARP9 polypeptide fragment, comprising at least eight contiguous amino acids of residues 1-83 of SEQ ID NO:
- 10.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP9 binding agent that selectively binds an ARP9 polypeptide;
- (b) determining a test expression level of ARP9 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP9 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP9 regulatory agent.
A substantially pure ARP13 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP13 polypeptide having at least 90% amino acid identity with SEQ ID NO:
- 12.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP13 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 11;
- (b) determining a test expression level of ARP13 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP13 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP13 polypeptide, comprising an amino acid sequence having at least 90% amino acid identity with SEQ ID NO:
- 12.
A substantially pure ARP13 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 12.
An ARP13 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of the ARP13 polypeptide SEQ ID NO:
- 12.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP13 binding agent that selectively binds an ARP13 polypeptide;
- (b) determining a test expression level of ARP13 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP13 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP13 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP20 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 13;
- (b) determining a test expression level of ARP20 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP20 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP20 polypeptide, comprising an amino acid sequence having at least 55% amino acid identity with SEQ ID NO:
- 14.
A substantially pure ARP20 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 14.
An ARP20 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of the ARP20 polypeptide SEQ ID NO:
- 14.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP20 binding agent that selectively binds an ARP20 polypeptide;
- (b) determining a test expression level of ARP20 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP20 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP20 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP24 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 15;
- (b) determining a test expression level of ARP24 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP24 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP24 polypeptide, comprising an amino acid sequence having at least 30% amino acid identity with SEQ ID NO:
- 16.
A substantially pure ARP24 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 16.
An ARP24 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of the ARP24 polypeptide SEQ ID NO:
- 16.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP24 binding agent that selectively binds an ARP24 polypeptide;
- (b) determining a test expression level of ARP24 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP24 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP24 regulatory agent.
A substantially pure ARP26 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 17.
A substantially pure ARP26 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1404-1516 of SEQ ID NO:
- 17.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP26 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 17;
- (b) determining a test expression level of ARP26 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP26 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP26 binding agent that selectively binds an ARP26 polypeptide;
- (b) determining a test expression level of ARP26 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP26 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP26 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP28 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 19;
- (b) determining a test expression level of ARP28 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP28 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP28 binding agent that selectively binds an ARP28 polypeptide;
- (b) determining a test expression level of ARP28 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP28 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP28 regulatory agent.
A substantially pure ARP30 nucleic acid molecule, comprising a nucleic acid sequence encoding an ARP30 polypeptide having at least 30% amino acid identity with SEQ ID NO:
- 22.
A substantially pure ARP30 nucleic acid molecule, comprising at least 10 contiguous nucleotides of a sequence selected from the group consisting of:
- nucleotides 1-132 of SEQ ID NO:
- 21, nucleotides 832-1696 of SEQ ID NO:
- 21 and nucleotides 2346-2796 of SEQ ID NO:
- 21.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP30 nucleic acid molecule comprising at least 10 contiguous nucleotides of nucleotides 1-1829 or nucleotides 2346-3318 of SEQ ID NO:
- 21;
- (b) determining a test expression level of ARP30 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP30 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP30 polypeptide, comprising an amino acid sequence having at least 30% amino acid identity with SEQ ID NO:
- 22.
A substantially pure ARP30 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:
- 22.
An ARP30 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of the ARP30 polypeptide SEQ ID NO:
- 22.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP30 binding agent that selectively binds an ARP30 polypeptide;
- (b) determining a test expression level of ARP30 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP30 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP30 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP33 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 23;
- (b) determining a test expression level of ARP33 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP33 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP33 polypeptide, comprising an amino acid sequence having at least 70% amino acid identity with SEQ ID NO:
- 24.
A substantially pure ARP33 polypeptide fragment, comprising at least eight contiguous amino acids of residues 1-132 or 251-405 of SEQ ID NO:
- 24.
An ARP33 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of residues 1-132 or 251-405 of SEQ ID NO:
- 24.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP33 binding agent that selectively binds an ARP33 polypeptide;
- (b) determining a test expression level of ARP33 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP33 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP33 regulatory agent.
A substantially pure ARP6 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 25.
A substantially pure ARP6 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 505-526 of SEQ ID NO:
- 25.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP6 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 25;
- (b) determining a test expression level of ARP6 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP6 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP6 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP10 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 26;
- (b) determining a test expression level of ARP10 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP10 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP10 regulatory agent.
A substantially pure ARP12 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 27.
A substantially pure ARP12 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1635-1659 of SEQ ID NO:
- 27.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP12 nucleic acid molecule comprising at least 10 contiguous nucleotides of nucleotides 1-1659 or 2176-2576 of SEQ ID NO:
- 27;
- (b) determining a test expression level of ARP12 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP12 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP12 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP18 nucleic acid molecule comprising at least contiguous nucleotides of SEQ ID NO:
- 28;
- (b) determining a test expression level of ARP18 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP18 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP18 regulatory agent.
A substantially pure ARP19 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 29.
A substantially pure ARP19 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1-31 and 478-644 of SEQ ID NO:
- 29.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP19 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 29;
- (b) determining a test expression level of ARP19 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP19 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP19 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP21 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 30;
- (b) determining a test expression level of ARP21 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP21 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP21 regulatory agent.
A substantially pure ARP22 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 31.
A substantially pure ARP22 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1-73 or 447-464 of SEQ ID NO:
- 31.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP22 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 31;
- (b) determining a test expression level of ARP22 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP22 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP22 regulatory agent.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP29 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:
- 32;
- (b) determining a test expression level of ARP29 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP29 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP29 regulatory agent.
A substantially pure ARP11 nucleic acid molecule, comprising the nucleotide sequence shown as SEQ ID NO:
- 33.
A substantially pure ARP11 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1-458 of SEQ ID NO:
- 33.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a sample from said individual with an ARP11 nucleic acid molecule comprising at least 10 contiguous nucleotides of nucleotides 1-458 of SEQ ID NO:
- 33;
- (b) determining a test expression level of ARP11 RNA in said sample;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP11 RNA,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A substantially pure ARP11 polypeptide, comprising an amino acid sequence having at least 75% amino acid identity with SEQ ID NO:
- 34.
A substantially pure ARP11 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ.ID NO:
- 34.
An ARP11 binding agent, comprising a molecule that selectively binds at least eight contiguous amino acids of the ARP11 polypeptide SEQ ID NO:
- 34.
A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
- (a) contacting a specimen from said individual with an ARP11 binding agent that selectively binds an ARP11 polypeptide;
- (b) determining a test expression level of ARP11 polypeptide in said specimen;
- and
- (c) comparing said test expression level to a non-neoplastic control expression level of ARP11 polypeptide,
- wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.
A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP11 regulatory agent.
Dependencies are inferred from the claim text.